ECE2022 Poster Presentations Thyroid (136 abstracts)
Does the risk of new metabolic changes among thyroid cancer survivors depend upon thyroid function?
Elena Izkhakov 1,2 , Yacov Shacham 2,3 , Tomer Ziv-Baran 4 , Iris Yaish 1,2 , Gilad Horowitz 2,5 , Anton Warshavsky 2,5 , Nidal Muhanna 2,5 , Narin Nard Carmel-Neidermann 2,5 , Karen Tordjman 1,2 & Yona Greenman 1,2
1Tel Aviv Sourasky Medical Center, lnstitute of Endocrinology, Diabetes, Metabolism and Hypertension, Tel Aviv-Yafo, Israel; 2Tel Aviv University, Tel Aviv-Yafo, Israel; 3Tel Aviv Sourasky Medical Center, Department of Cardiology, Tel Aviv-Yafo, Israel; 4Tel Aviv University, School of Public Health, Sackler Faculty of Medicine, Tel Aviv-Yafo, Israel; 5Tel Aviv Sourasky Medical Center, Department of Otolaryngology, Head & Neck and Maxillofacial Surgery, Tel Aviv-Yafo, Israel
Background: Various components of metabolic syndrome (MS) significantly increase the risk of thyroid cancer (TC). Moreover, thyroid cancer survivors (TCS) are at increased risk of new components of MS (MSC). The role of thyroid function in this context has not yet been determined. We investigated changes in selected MSC and their association with thyroid function during a two-year follow-up among TCS.
Materials and Methods: This retrospective, nested case-control study used data from a single academic hospital. The one-hundred and fifteen participants had undergone total thyroidectomy, radioactive iodine treatment and thyroid-stimulating hormone-suppressive L-thyroxine therapy for two years due to differentiated TC.
Results: The numbers of MSC in the entire cohort at baseline compared to those after a two-year follow-up were as follows: none in 58.3% patients vs 30.4% patients, respectively, 1 in 20.9% vs 35.7%; 2 in 11.3% vs 16.5%; 3 in 7.8% vs 13.9%; 4 in 1.7% vs 1.7%; and 5 in 0% vs 1.7%. The incidence of MSC increased during the two-year follow-up period in 51 TCS (cases), while none of the 64 TCS (controls) developed any new MSC. The multivariable logistic regression analysis showed that TCS with a FT3/FT4 ratio greater than 0.22 (lower tertile) had a significantly increased risk of a new MSC (odds ratio 2.73, 95% confidence interval 1.14−6.57, P=0.025).
Conclusions: Our study demonstrated that an FT3/FT4 ratio greater than 0.22 is correlated with detrimental metabolic changes among TCS.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more